Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
KCNV2 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, WB, E |
|---|---|
| Primary Accession | Q8TDN2 |
| Other Accession | Q8CFS6, NP_598004.1 |
| Reactivity | Human |
| Predicted | Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 62459 Da |
| Antigen Region | 478-507 aa |
| Gene ID | 169522 |
|---|---|
| Other Names | Potassium voltage-gated channel subfamily V member 2, Voltage-gated potassium channel subunit Kv82, KCNV2 |
| Target/Specificity | This KCNV2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 478-507 amino acids from the C-terminal region of human KCNV2. |
| Dilution | IHC-P~~1:10~50 WB~~1:1000 E~~Use at an assay dependent concentration. |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | KCNV2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | KCNV2 |
|---|---|
| Function | Potassium channel subunit. Modulates channel activity by shifting the threshold and the half-maximal activation to more negative values. |
| Cellular Location | Cell membrane; Multi-pass membrane protein. Note=Has to be associated with KCNB1 or possibly another partner to get inserted in the plasma membrane. Remains intracellular in the absence of KCNB1 |
| Tissue Location | Detected in lung, liver, kidney, pancreas, spleen, thymus, prostate, testis, ovary and colon |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium voltage-gated channel subfamily V. This member is identified as a 'silent subunit', and it does not form homomultimers, but forms heteromultimers with several other subfamily members. Through obligatory heteromerization, it exerts a function-altering effect on other potassium channel subunits. This protein is strongly expressed in pancreas and has a weaker expression in several other tissues.
References
Robson, A.G., et al. Retina (Philadelphia, Pa.) 30(1):51-62(2010)
Ben Salah, S., et al. Am. J. Ophthalmol. 145(6):1099-1106(2008)
Wissinger, B., et al. Invest. Ophthalmol. Vis. Sci. 49(2):751-757(2008)
Thiagalingam, S., et al. Ophthalmic Genet. 28(3):135-142(2007)
Balijepalli, R.C., et al. Channels (Austin) 1(4):263-272(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
